<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Masood M</submitter><funding>HEC NRPU</funding><pagination>e14124</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9703992</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Breast cancer is the second leading cause of cancer-related deaths globally, and its prevalence rates are increasing daily. In the past, studies predicting therapeutic drug targets for cancer therapy focused on the assumption that one gene is responsible for producing one protein. Therefore, there is always an immense need to find promising and novel anti-cancer drug targets. Furthermore, proteases have an integral role in cell proliferation and growth because the proteolysis mechanism is an irreversible process that aids in regulating cellular growth during tumorigenesis. Therefore, an inactive rhomboid protease known as iRhom2 encoded by the gene RHBDF2 can be considered an important target for cancer treatment. Speculatively, previous studies on gene expression analys</pubmed_abstract><journal>PeerJ</journal><pubmed_title>Investigating isoform switching in &lt;i>RHBDF2&lt;/i> and its role in neoplastic growth in breast cancer.</pubmed_title><pmcid>PMC9703992</pmcid><funding_grant_id>9988</funding_grant_id><pubmed_authors>Paracha RZ</pubmed_authors><pubmed_authors>Masood M</pubmed_authors><pubmed_authors>Us Subah N</pubmed_authors><pubmed_authors>Shabbir M</pubmed_authors><pubmed_authors>Masood MBE</pubmed_authors><pubmed_authors>Rafiq M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Investigating isoform switching in &lt;i>RHBDF2&lt;/i> and its role in neoplastic growth in breast cancer.</name><description>&lt;h4>Background&lt;/h4>Breast cancer is the second leading cause of cancer-related deaths globally, and its prevalence rates are increasing daily. In the past, studies predicting therapeutic drug targets for cancer therapy focused on the assumption that one gene is responsible for producing one protein. Therefore, there is always an immense need to find promising and novel anti-cancer drug targets. Furthermore, proteases have an integral role in cell proliferation and growth because the proteolysis mechanism is an irreversible process that aids in regulating cellular growth during tumorigenesis. Therefore, an inactive rhomboid protease known as iRhom2 encoded by the gene RHBDF2 can be considered an important target for cancer treatment. Speculatively, previous studies on gene expression analys</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2026-05-28T21:26:48.416Z</modification><creation>2024-11-21T01:22:52.977Z</creation></dates><accession>S-EPMC9703992</accession><cross_references><pubmed>36452073</pubmed><doi>10.7717/peerj.14124</doi></cross_references></HashMap>